IGC Pharma to present AI platforms for AD at AAIC 2025

IGC Pharma (IGC) announced the presentation of three scientific posters at the 2025 Alzheimer’s Association International Conference, taking place July 27-31 in Toronto, Canada. The poster presentations highlight advancements in the Company’s proprietary artificial intelligence platforms designed to accelerate drug discovery and improve early detection of Alzheimer’s disease, particularly in low-resource settings. IGC Pharma’s team will be participating in person. At the AAIC 2025, IGC’s team will present: Title: Multimodal Interpretable Transformer for AD: Highlights: The poster introduces MINT-AD, an AI foundation model being trained on over 100 globally diverse datasets to stratify Alzheimer’s risk and forecast cognitive decline. Designed to empower general practitioners, MINT-AD integrates clinical, demographic, and lifestyle data to produce personalized, interpretable Alzheimer’s risk assessments and predict cognitive decline. MINT-AD enables the earlier identification and intervention for over 400 million individuals globally with early disease pathology who could potentially benefit. Title: MINT-AD: Early Prediction of MMSE & CSI-D Scores with AI Highlights: IGC will present research demonstrating the use of large language models to accurately predict Mini Mental State Exam and Community Screening Instrument for Dementia cognitive scores. Crucially, these predictions are made using socioeconomic data alone, in the absence of brain scan or blood biomarker data, offering a highly scalable, accessible approach to support clinicians in predicting cognitive decline trajectories and guiding early interventions. Title: AI in the Drug Discovery Pipeline Highlights: This poster details IGC’s hybrid in-silico and in-vitro pipeline, which utilizes AI-powered screening models to rapidly identify and optimize interactions between proprietary molecules and Alzheimer’s-relevant targets, including GLP-1 and CB1. The results highlight strong predictive capabilities, demonstrating significant promise for accelerating future in vitro validation and compound optimization efforts in Alzheimer’s disease discovery.